Cleared Traditional

K780729 - LAS-R HUMAN COMPLEMENT CLQ TEST

K780729 is the FDA 510(k) clearance for LAS-R HUMAN COMPLEMENT CLQ TEST by Hyland Therapeutic Div., Travenol Laboratories. It is a Class 2 Immunology device (product code DAK) cleared through the Traditional 510(k) pathway after a 16-day FDA review.

K780729 · Hyland Therapeutic Div., Travenol Laboratories · Immunology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
May 1978
Decision
16d
Days
Class 2
Risk

K780729 is an FDA 510(k) clearance for the LAS-R HUMAN COMPLEMENT CLQ TEST. Classified as Complement C1q, Antigen, Antiserum, Control (product code DAK), Class II - Special Controls.

Submitted by Hyland Therapeutic Div., Travenol Laboratories (Mchenry, US). The FDA issued a Cleared decision on May 18, 1978 after a review of 16 days - a notably fast clearance cycle.

This device falls under the Immunology FDA review panel, regulated under 21 CFR 866.5240 - the FDA immunology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Hyland Therapeutic Div., Travenol Laboratories devices

Submission Details

510(k) Number K780729 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received May 02, 1978
Decision Date May 18, 1978
Days to Decision 16 days
Submission Type Traditional
Review Panel Immunology (IM)
Summary -
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
88d faster than avg
Panel avg: 104d · This submission: 16d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code DAK Complement C1q, Antigen, Antiserum, Control
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.5240
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Immunology devices follow this clearance model.

Regulatory Peers - DAK Complement C1q, Antigen, Antiserum, Control

All 13
Devices cleared under the same product code (DAK) and FDA review panel - the closest regulatory comparables to K780729.
ORTHO CLG IMMUNE COMPLEX TEST SYSTEM
K821806 · Ortho Diagnostic Systems, Inc. · Jun 1982
ELECTRO-IMMUNO-QUANTITATION (EIQ)
K792472 · Icl Scientific · Dec 1979
ANTI-HUMAN CIQ SERUM
K781022 · Icl Scientific · Aug 1978
HUMAN REFERENCE SERUM C4 COMPLEMENT
K772003 · G.D. Searle and Co. · Nov 1977
GOAT ANTISERUM COMPLEMENT C3 NEPHEL.
K770964 · Kallestad Laboratories, Inc. · Jun 1977
LAS-R TM HUMAN COMPLEMENT C4 TEST
K770547 · Hyland Therapeutic Div., Travenol Laboratories · May 1977